science pharmaceutical expo biotech jobs
Originally published online as doi:10.1189/jlb.1104655 on April 27, 2005

Published online before print April 27, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1104655v1
78/1/289    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hickey, F. B.
Right arrow Articles by Cotter, T. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hickey, F. B.
Right arrow Articles by Cotter, T. G.
(Journal of Leukocyte Biology. 2005;78:289-300.)
© 2005 by Society for Leukocyte Biology

Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK

Fionnuala B. Hickey, Karen England and Thomas G. Cotter1

Department of Biochemistry, Biosciences Institute, University College Cork, Ireland

1 Correspondence: Department of Biochemistry, Biosciences Institute, University College Cork, Cork, Ireland. E-mail: t.cotter{at}ucc.ie

Chronic myeloid leukemia (CML) is caused by the constitutively active Bcr-Abl tyrosine kinase. This fusion protein is generated by the Philadelphia translocation t(9;22). CML is a progressive condition that invariably advances from a drug-sensitive to a drug-resistant, aggressive, acute leukemia. The mechanisms responsible for this progression are largely unknown; however, in many cases, progression is accompanied by an increase in Bcr-Abl expression. Osteopontin (OPN) expression has been shown to be involved in the progression and increased aggression and invasiveness of many solid tumors. Here, we demonstrate that OPN expression is induced in a model of leukemia, and we describe the identification of specific signaling pathways required for the induction of OPN expression by p210 Bcr-Abl. We have determined that high levels of Bcr-Abl activate a signaling cascade involving the sequential activation of Ras, phosphatidylinositol-3 kinase, atypical protein kinase C, Raf-1, and mitogen-activated protein kinase kinase, leading to the ultimate expression of OPN. Our results suggest that these molecules represent a single pathway and also that there is no redundancy in this pathway, as inhibition of any individual component results in a block in the induction of OPN. The data presented here define for the first time the ability of Bcr-Abl to stimulate the expression of OPN and also identify the signaling pathway involved. This may not only prove important in understanding the mechanisms of progression of CML but also highlights a pathway that may prove significant in many other cases of oncogenesis, where OPN expression is implicated.

Key Words: chronic myeloid leukemia • cellular signaling • gene expression




This article has been cited by other articles:


Home page
ASH Education BookHome page
C. H. Jamieson
Chronic Myeloid Leukemia Stem Cells
Hematology, January 1, 2008; 2008(1): 436 - 442.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Juric, N. J. Lacayo, M. C. Ramsey, J. Racevskis, P. H. Wiernik, J. M. Rowe, A. H. Goldstone, P. J. O'Dwyer, E. Paietta, and B. I. Sikic
Differential Gene Expression Patterns and Interaction Networks in BCR-ABL-Positive and -Negative Adult Acute Lymphoblastic Leukemias
J. Clin. Oncol., April 10, 2007; 25(11): 1341 - 1349.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Schapira, G. Lazer, and S. Katzav
Osteopontin Is an Oncogenic Vav1- but not Wild-type Vav1-Responsive Gene: Implications for Fibroblast Transformation.
Cancer Res., June 15, 2006; 66(12): 6183 - 6191.
[Abstract] [Full Text] [PDF]